Comparative Pharmacology
Head-to-head clinical analysis: METOZOLV ODT versus VONTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METOZOLV ODT versus VONTROL.
METOZOLV ODT vs VONTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective 5-HT3 receptor antagonist; blocks serotonin action at vagal nerve terminals and in the chemoreceptor trigger zone, inhibiting emetic reflex.
VONTROL (trimethobenzamide) acts centrally to inhibit the chemoreceptor trigger zone (CTZ) in the medulla oblongata, thereby suppressing nausea and vomiting. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and serotonin 5-HT3 receptors.
2.5 mg to 5 mg orally once daily, as disintegrating tablet; may increase to 10 mg if needed
10 mg orally twice daily; maximum 20 mg/day.
None Documented
None Documented
~1.5–2 hours in normal renal function; prolonged to 10–20 hours in severe renal impairment (CrCl <30 mL/min).
12 hours; prolonged in renal impairment (up to 24 hours in ESRD)
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Renal: 60% unchanged; fecal: 30% (biliary); hepatic metabolism: 10%
Category C
Category C
Antiemetic
Antiemetic